Recursion Pharmaceuticals, Inc. (BMV:RXRX)

Mexico flag Mexico · Delayed Price · Currency is MXN
89.00
+5.01 (5.96%)
At close: Dec 4, 2025
Market Cap 44.67B
Revenue (ttm) 801.35M
Net Income (ttm) -13.12B
Shares Out n/a
EPS (ttm) -32.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 180
Average Volume 29,851
Open 89.00
Previous Close 83.99
Day's Range 89.00 - 89.00
52-Week Range 70.95 - 219.00
Beta n/a
RSI 46.18
Earnings Date Feb 27, 2026

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 800
Stock Exchange Mexican Stock Exchange
Ticker Symbol RXRX
Full Company Profile

Financial Performance

In 2024, Recursion Pharmaceuticals's revenue was $58.84 million, an increase of 32.00% compared to the previous year's $44.58 million. Losses were -$463.66 million, 41.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.